Phaseline

Targets › CD33

CD33 (Myeloid cell surface antigen CD33): drug programs, companies and trials

24 programs from 23 companies in 27 trials: 15 Phase 1, 9 Phase 2, 3 Phase 3; Oncology, Hematology; next expected readout Dec 2026.

Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. (UniProt, P20138)

Open in Phaseline: the race on CD33, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gruppo Italiano Malattie EMatologiche dell'AdultoGemtuzumab ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 3Acute Myeloid LeukemiaApr 2027
Princess Maxima Center for Pediatric OncologyGemtuzumab
Myeloid cell surface antigen CD33 binding agent
CD33Phase 3Acute Myeloid Leukemia in ChildrenMar 2031
University of BirminghamGemtuzumab ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 3Acute Myeloid LeukaemiaDec 2031
University of WashingtonGemtuzumab Ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 2Acute Myeloid LeukemiaDec 2026
National Cancer Institute (NCI)Gemtuzumab Ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 2Acute Myeloid Leukemia; Core Binding Factor Acute Myeloid LeukemiaMar 2027
University of Maryland, BaltimoreGemtuzumab ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 2Acute Myeloid Leukemia, AdultJun 2027
Associazione Italiana Ematologia Oncologia PediatricaGemtuzumab Ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 2Acute Promyelocytic LeukemiaOct 2027
M.D. Anderson Cancer CenterGemtuzumab Ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 2Acute Promyelocytic Leukemia With PML-RARA; Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Dec 2027
Centre Antoine LacassagneGemtuzumab ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 2AMLJul 2028
Shaare Zedek Medical CenterGemtuzumab Ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 2Leukemia, Myeloid, AcuteSep 2028
Essen BiotechCD123/CD33 CAR-T (EB-BH2025)
CAR-T cells targeting CD123 and/or CD33 sequentially
CD123, CD33Phase 1AMLDec 2026
First Affiliated Hospital of Zhejiang UniversityA-CAR028
Bispecific chimeric antigen receptor T-cell targeting CD33 and CLL-1
CD33, ITGA4Phase 1Acute Myeloid Leukemia (AML)Dec 2026
Beijing GoBroad HospitalFL-33 CAR T therapy
anti-CD33 CAR-T cell therapy
CD33Phase 1Refractory/Relapsed Acute Myeloid LeukaemiaDec 2026
Masonic Cancer Center, University of MinnesotaGTB-3650
Tri-specific killer engager (TriKE) targeting CD16 on NK cells, IL-15 co-stimulation, and
CD16, IL15, CD33Phase 1Myeloid MalignancyMar 2027
H. Lee Moffitt Cancer Center and Research InstituteGemtuzumab Ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 1Acute Myeloid LeukemiaApr 2027
Technische Universität DresdenGemtuzumab ozogamicin
Myeloid cell surface antigen CD33 binding agent
CD33Phase 1Acute Myeloid LeukemiaApr 2027
Seattle Children's HospitalSC-DARIC33
Anti-CD33 CAR-T cell therapy with DARIC (Dimerizing Agent Regulated Immunoreceptor Complex
CD33Phase 1Acute Myeloid LeukemiaFeb 2028
University of VirginiaCD33 FPBMC
anti-CD3 x anti-CD33 bispecific antibody armed fresh peripheral blood mononuclear cells
CD3E, CD33Phase 1Acute Myeloid LeukemiaAug 2028
City of Hope Medical CenterAnti-CD33 CAR T-cells
anti-CD33 chimeric antigen receptor (CAR) T-cell therapy
CD33Phase 1Acute Myeloid LeukemiaSep 2028
University of PennsylvaniaCD33KO-HSPC
CD33-knockout hematopoietic stem and progenitor cells to reduce CAR-T cell toxicity
CD33Phase 1Leukemia, Myeloid, AcuteFeb 2029
Center for International Blood and Marrow Transplant ResearchCD33CART allogeneic
anti-CD33 chimeric antigen receptor-expressing T cells
CD33Phase 1Acute Myelogenous LeukemiaDec 2029
Center for International Blood and Marrow Transplant ResearchCD33CART autologous
anti-CD33 chimeric antigen receptor-expressing T cells
CD33Phase 1Acute Myelogenous LeukemiaDec 2029
Great Ormond Street Hospital for Children NHS Foundation TrustBE CAR33 (Cryopreserved BE CAR33 T Cells / BE752TBTTBCAR33PBL)
Base-edited CAR-T cells targeting CD33 with enhanced safety profile through base editing t
CD33Phase 1Relapsed Acute Myeloid Leukaemia–
PrecigenPRGN-3006 T Cells
Anti-CD33 chimeric antigen receptor (CAR) T cell therapy
CD33Phase 1Acute Myeloid Leukemia–

Conditions

Acute Myeloid Leukemia (9) Leukemia, Myeloid, Acute (3) AML (2) Acute Myelogenous Leukemia (2) Acute Myeloid Leukemia in Children (1) Refractory/Relapsed Acute Myeloid Leukaemia (1) Acute Promyelocytic Leukemia With PML-RARA (1) Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 (1) Core Binding Factor Acute Myeloid Leukemia (1) Relapsed Acute Myeloid Leukaemia (1) Myeloid Malignancy (1) Acute Myeloid Leukaemia (1)

Modalities

other (7), small molecule (5), mixed (5), antibody (4), protein or peptide (3)

Companies

Center for International Blood and Marrow Transplant Research (2) Princess Maxima Center for Pediatric Oncology (1) Beijing GoBroad Hospital (1) Shaare Zedek Medical Center (1) University of Washington (1) Seattle Children's Hospital (1) M.D. Anderson Cancer Center (1) City of Hope Medical Center (1) National Cancer Institute (NCI) (1) University of Pennsylvania (1) Great Ormond Street Hospital for Children NHS Foundation Trust (1) H. Lee Moffitt Cancer Center and Research Institute (1) Masonic Cancer Center, University of Minnesota (1) Essen Biotech (1) Gruppo Italiano Malattie EMatologiche dell'Adulto (1) University of Virginia (1) Technische Universität Dresden (1) Precigen (1) University of Birmingham (1) Associazione Italiana Ematologia Oncologia Pediatrica (1)

Related targets

CD16 (1) IL15 (1) CD123 (1) CD3E (1) ITGA4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.